Nuo Therapeutics director exercises 50,000 stock options in net exercise

Nuo Therapeutics, Inc. director reports stock option exercise.

Rhea-AI Filing Summary

Nuo Therapeutics, Inc. director reports stock option exercise. A director of Nuo Therapeutics exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share through a net exercise on December 9, 2025. The transaction resulted in the director receiving 40,909 shares of common stock, while 9,091 shares underlying the option were withheld to cover the exercise price using a closing market price of $2.20 per share. Following these transactions, the director beneficially owns 108,294 shares of Nuo Therapeutics common stock in direct ownership.

Insider Trade Summary

50,000 shares exercised/converted

Exercise 3 txns

Insider Mintz Paul

Role Director

Type	Security	Shares	Price	Value
Exercise	Common Stock	50,000	$0.40	$20K
Exercise Price or Tax Liability	Common Stock	9,091	$2.20	$20K
Exercise	Option to purchase common stock	50,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 0 contracts (Direct); Common Stock — 108,294 shares (Direct)

Footnotes (1)

1. F1. Represents a net exercise of outstanding stock options. The reporting person received 40,909 shares of common stock on the net exercise of option to purchase 50,000 shares of common stock. The issuer withheld 9,091 shares of common stock underlying the option for payment of the exercise price using the closing price of $2.20.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuo Therapeutics (AURX) report in this Form 4/A?

A director of Nuo Therapeutics reported exercising an option to purchase 50,000 shares of common stock through a net exercise on December 9, 2025.

How many Nuo Therapeutics (AURX) shares did the director receive from the option exercise?

The director received 40,909 shares of Nuo Therapeutics common stock as a result of the net exercise of options.

How many Nuo Therapeutics (AURX) shares were withheld to pay the option exercise price?

The issuer withheld 9,091 shares of common stock underlying the option to pay the exercise price, using a closing price of $2.20 per share.

What was the exercise price of the stock options for the Nuo Therapeutics (AURX) director?

The options exercised by the director had an exercise price of $0.40 per share for Nuo Therapeutics common stock.

How many Nuo Therapeutics (AURX) shares does the director own after this transaction?

After the reported transactions, the director beneficially owns 108,294 shares of Nuo Therapeutics common stock in direct ownership.

What is a net exercise of stock options as used in this Nuo Therapeutics (AURX) filing?

In this case, a net exercise means the director exercised options for 50,000 shares and received 40,909 shares while 9,091 shares were withheld by the issuer to pay the exercise cost.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 09:55 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mintz Paul

(Last) (First) (Middle)

C/O NUO THERAPEUTICS, INC.

8285 EL RIO, SUITE190

(Street)

HOUSTON TX 77054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuo Therapeutics, Inc. [ AURX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
12/11/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		M		50,000	A	$0.4	117,385	D
Common Stock	12/09/2025		F(1)		9,091	D	$2.2	108,294	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$0.4	12/31/2018		M			50,000	12/31/2018	12/31/2025	Common Stock	50,000	$0	0	D

Explanation of Responses:

1. Represents a net exercise of outstanding stock options. The reporting person received 40,909 shares of common stock on the net exercise of option to purchase 50,000 shares of common stock. The issuer withheld 9,091 shares of common stock underlying the option for payment of the exercise price using the closing price of $2.20.

	/s/ David Jorden, attorney-in-fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.